['squamous non-small cell lung cancer']
['carboplatin', 'veliparib', 'paclitaxel', 'placebo to veliparib']

        Inclusion Criteria:

          1. Life expectancy > 12 weeks

          2. Subject must have cytologically or histologically confirmed squamous NSCLC.

          3. Subject must have advanced or metastatic squamous NSCLC that is not amenable to
             surgical resection or radiation with curative intent at time of study Screening.

          4. Subjects with recurrent squamous NSCLC after surgical treatment that is not amenable
             to surgical resection or radiation with curative intent are eligible.

          5. Subject must have at least 1 unidimensional measurable NSCLC lesion on a computerized
             tomography (CT) scan as defined by Response Evaluation Criteria In Solid Tumors
             (RECIST - version 1.1).

        Exclusion Criteria:

          1. Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with
             polyethoxylated castor oil (Cremophor).

          2. Subject has a known hypersensitivity to platinum compounds.

          3. Subject has peripheral neuropathy >= grade 2.

          4. Subject has non-squamous NSCLC, or a known epidermal growth factor receptor (EGFR)
             mutation of exon 19 deletion or L858R mutation in exon 21, or a known anaplastic
             lymphoma kinase (ALK) gene rearrangement.

          5. Subject has received prior cytotoxic chemotherapy (including definitive
             chemoradiotherapy) for NSCLC, except for adjuvant or neoadjuvant therapy.
      